专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008080091A2 ACTIVATION OF RIG-I PATHWAY 审中-公开
标题翻译： RIG-I PATHWAY的启动
公开(公告)号：WO2008080091A2
公开(公告)日：2008-07-03
申请号：PCT/US2007/088620
申请日：2007-12-21
申请人： VICAL INCORPORATED , SMITH, Larry, R. , YANG, Catherine, K.
发明人： SMITH, Larry, R. , YANG, Catherine, K.
IPC分类号： A61K39/39 , A61K39/385 , A61K39/145 , A61K39/00 , A61K39/04 , A61K39/015 , A61K39/12 , A61P31/16
CPC分类号： A61K39/00 , A61K39/12 , A61K39/145 , A61K2039/53 , A61K2039/55561 , C12N15/117 , C12N2310/111 , C12N2310/17 , C12N2760/16134 , Y02A50/412
摘要： The disclosed invention relates to nucleic acid molecules and compositions thereof for stimulating or enhancing an immune response in a subject. Methods for the use of the molecules and compositions, including administration of the molecules or compositions to a subject to facilitate an immune response to a vector encoded antigen are also described.
摘要翻译：所公开的发明涉及用于刺激或增强受试者的免疫应答的核酸分子及其组合物。还描述了使用分子和组合物的方法，包括向受试者施用分子或组合物以促进对载体编码的抗原的免疫应答。

2. 发明申请

WO2005116270A2 INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE 审中-公开
标题翻译：流感病毒疫苗组合物及其使用方法
公开(公告)号：WO2005116270A2
公开(公告)日：2005-12-08
申请号：PCT/US2005/017157
申请日：2005-05-18
申请人： VICAL INCORPORATED , LUKE, Catherine , VILALTA, Adrian , WLOCH, Mary, K. , GEALL, Andrew , EVANS, Thomas, G. , JIMENEZ, Gretchen, S.
发明人： LUKE, Catherine , VILALTA, Adrian , WLOCH, Mary, K. , GEALL, Andrew , EVANS, Thomas, G. , JIMENEZ, Gretchen, S.
IPC分类号： C12Q1/70
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K2039/53 , A61K2039/54 , A61K2039/55511 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C07K16/1018 , C07K2317/34 , C12N2760/16134 , C12N2760/16151
摘要： The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo , into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo , into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo , and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo . The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
摘要翻译：本发明涉及通过在体内施用人体组织来增强需要防止IV感染的人的免疫应答，所述至少一种多核苷酸包含一个或多个编码IV蛋白的核酸区域或片段，变体或其衍生物。本发明进一步涉及通过在体内施用人体组织，至少一种IV蛋白或其片段，变体或衍生物来增强需要保护免受IV感染的人的免疫应答。 IV蛋白可以是例如纯化形式或可以是灭活的IV，例如存在于灭活IV疫苗中的那些。将多核苷酸体内并入人的细胞中，并且在体内产生免疫有效量的IV或其片段，变体或衍生物的免疫原性表位。 IV蛋白（以纯化形式或灭活IV疫苗的形式）也以免疫有效量施用。

3. 发明申请

WO2009005917A2 METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS 审中-公开
标题翻译：治疗哺乳动物传染性疾病的方法
公开(公告)号：WO2009005917A2
公开(公告)日：2009-01-08
申请号：PCT/US2008/065152
申请日：2008-05-29
申请人： VICAL INCORPORATED , JOHNS HOPKINS UNIVERSITY , VILALTA, Adrian , JIMENEZ, Gretchen , GRIFFIN, Diane, E.
发明人： VILALTA, Adrian , JIMENEZ, Gretchen , GRIFFIN, Diane, E.
IPC分类号： C07K14/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/165 , A61K2039/53 , A61K2039/541 , A61K2039/55555 , C12N2760/18422 , C12N2760/18434 , C12N2800/22
摘要： The invention provides for a measles vaccine utilizing a human codon-optimized polynucleotide encoding a measles virus polypeptide, such as HA or F protein. Optionally, the vaccine is administered with an adjuvant and is especially useful for immunizing an infant mammal.
摘要翻译：本发明提供了利用编码麻疹病毒多肽（例如HA或F蛋白）的人密码子优化的多核苷酸的麻疹疫苗。任选地，疫苗与佐剂一起施用，并且特别用于免疫婴儿哺乳动物。

4. 发明申请

WO2008148057A3 CATIONIC LIPIDS COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO VACCINES 审中-公开
公开(公告)号：WO2008148057A3
公开(公告)日：2008-12-04
申请号：PCT/US2008/064786
申请日：2008-05-23
申请人： VICAL INCORPORATED , HARTIKKA, Jukka , SULLIVAN, Sean, M. , ENAS, Joel, D. , ROLLAND, Alain
发明人： HARTIKKA, Jukka , SULLIVAN, Sean, M. , ENAS, Joel, D. , ROLLAND, Alain
IPC分类号： C07D295/13 , C07C217/28 , A61K39/39 , A61K47/18 , A61P31/04 , A61P31/12 , A61P35/00 , C07D211/46
摘要： The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipidxo-lipid mixtures and methods for delivering formulated compositions.

5. 发明申请

WO2008011609A3 COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 审中-公开
公开(公告)号：WO2008011609A3
公开(公告)日：2008-01-24
申请号：PCT/US2007/074045
申请日：2007-07-20
申请人： VICAL INCORPORATED , UNIVERSITY OF WASHINGTON , MARGALITH, Michal , VILALTA, Adrian , KOELLE, David, M. , DONG, Lichun
发明人： MARGALITH, Michal , VILALTA, Adrian , KOELLE, David, M. , DONG, Lichun
IPC分类号： C12N15/38 , C12N15/86 , C07K16/08 , A61K31/70 , A61K39/245 , G01N33/569
摘要： The present invention relates to prophylactic and therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (HSV-2), in particular by introducing and expressing in a vertebrate a DNA vaccine encoding at least one of the HSV-2 proteins such as gD, VP11/12, VP 13/14 and/or VP22. Formulations based on Vaxfectin (TM) adjuvant and poloxamer were evaluated for their ability to boost the immune response to the HSV DNA vaccines.

6. 发明申请

WO2006060723A2 METHODS FOR PRODUCING BLOCK COPOLYMER/AMPHIPHILIC PARTICLES 审中-公开
标题翻译：生产嵌段共聚物/两亲性颗粒的方法
公开(公告)号：WO2006060723A2
公开(公告)日：2006-06-08
申请号：PCT/US2005/043770
申请日：2005-12-02
申请人： VICAL INCORPORATED , GEALL, Andrew
发明人： GEALL, Andrew
IPC分类号： A61K9/14
CPC分类号： A61K9/0019 , A61K9/1075 , A61K9/1694 , A61K9/19 , A61K9/5146
摘要： The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, composition comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a disease or condition, or delivering a biologically active molecule to cells in vitro comprising administration of the pharmaceutical compositions described herein.
摘要翻译：本发明涉及制备细胞递送颗粒的方法，药物组分 - 颗粒分散体，包含细胞递送颗粒的组合物和包含药物组分 - 颗粒分散体的药物组合物。该方法包括均质化包含两亲组分和嵌段共聚物的混合物以形成稳定的颗粒。本发明还涉及由要求保护的方法产生的细胞递送颗粒和药物组分 - 颗粒分散体以及包含它们的组合物。在某些实施方案中，细胞递送颗粒可以进一步包含共脂质。本发明进一步涉及在体外产生免疫应答，治疗或预防疾病或病症，或将生物活性分子递送至细胞的方法，包括给予本文所述的药物组合物。

7. 发明申请

WO2004060363A1 METHOD FOR PRODUCING STERILE POLYNUCLEOTIDE BASED MEDICAMENTS 审中-公开
标题翻译：用于生产基于多核苷酸的药物的方法
公开(公告)号：WO2004060363A1
公开(公告)日：2004-07-22
申请号：PCT/US2003/038119
申请日：2003-12-02
申请人： VICAL INCORPORATED
发明人： GEALL, Andrew , ENAS, Joel
IPC分类号： A61K31/08
CPC分类号： C07C219/14 , A61K9/1075 , C07C211/63 , C07C217/28 , C07C219/06 , Y10S977/797
摘要： The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.
摘要翻译：本发明涉及一种制备包含多核苷酸，嵌段共聚物和阳离子表面活性剂的制剂的新方法。通过当前方法制备的制剂适用于基于多核苷酸的药物。本文公开的合适的生产方法另外包括冷过滤多核苷酸，嵌段共聚物和阳离子表面活性剂的混合物，从而对制剂灭菌。本发明的方法也消除了对制剂的热循环的需要，从而减少在商业制造过程中生产大量制剂所需的时间和费用。本发明还涉及新型阳离子脂质。

8. 发明申请

WO2018237369A3 LIPID NANOPARTICLE (LNP)-MEDIATED DELIVERY OF A CRISPR-EXPRESSING PLASMID DNA FOR TREATING CHRONIC HEPATITIS B VIRUS INFECTION 审中-公开
公开(公告)号：WO2018237369A3
公开(公告)日：2018-12-27
申请号：PCT/US2018/039179
申请日：2018-06-23
申请人： VICAL INCORPORATED
发明人： SULLIVAN, Sean M. , SMITH, Larry , CLEMENTE, Brenda , WEI, Qun , YE, Ming , HAYASHI, Yasuhiro
IPC分类号： C12N15/113 , C12N15/85 , C12N9/22 , A61P31/20
摘要： Provided herein is a CRISPR-expressing plasmid DNA and a gene delivery system targeted to hepatocytes infected with hepatitis B virus. Also provided are methods of directing CRISPR system formation in such cells to ensure enhanced specificity for target recognition to alter, improve, or treat chronic HBV infection. In addition the CpG content of the expressing plasmid DNA has been minimized to reduce inflammation and maximize gene expression.

9. 发明申请

WO2007103565A3 WNV DNA VACCINE INCORPORATING A CMV/R BACKBONE AND EXPRESSING WNV PRM AND E PROTEINS 审中-公开
公开(公告)号：WO2007103565A3
公开(公告)日：2007-09-13
申请号：PCT/US2007/006068
申请日：2007-03-09
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , VICAL INCORPORATED , NABEL, Gary, J. , KASLOW, David , QUONG, Melanie
发明人： NABEL, Gary, J. , KASLOW, David , QUONG, Melanie
IPC分类号： A61K39/12 , A61P31/12
摘要： The invention is related to DNA plasmids comprising a regulatory R region from the 5' long terminal repeat (LTR) of human T-cell leukemia virus type 1 (HTLV-1) and a coding frame that encodes West Nile virus (WNV) prM, or modified prM with deletion of the first ten amino acids, and E in operable linkage to the cytomegalovirus early gene promoter (CMV), where the coding frame comprises (a) nt 424-2427, or 454-2427, of NY99, (b) a corresponding sequence of a different WNV strain, or (c) a nucleotide sequence that encodes WNV prM-E but differs from (a) and (b) due to codon degeneracy, or where the coding frame comprises a sequence having equal to or greater than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the sequence of the polypeptide expressed from (a) nt 424-2427, or 454-2427, of NY99, (b) a corresponding sequence of a different WNV strain, or (c) a nucleotide sequence that encodes WNV prM-E but differs from (a) and (b) due to codon degeneracy; and to immunogenic compositions, methods for inducing an immune response, and kits related thereto.

10. 发明申请

WO2005021707A2 SEVERE ACUTE RESPIRATORY SYNDROME DNA VACCINE COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：严重急性呼吸综合征DNA疫苗组合物及使用方法
公开(公告)号：WO2005021707A2
公开(公告)日：2005-03-10
申请号：PCT/US2004/015512
申请日：2004-05-17
申请人： VICAL INCORPORATED , VILALTA, Adrian , EVANS, Thomas, G. , QUONG, Melanie, W. , MANTHORPE, Marston
发明人： VILALTA, Adrian , EVANS, Thomas, G. , QUONG, Melanie, W. , MANTHORPE, Marston
IPC分类号： C12N
CPC分类号： A61K39/215 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/55511 , A61K2039/55555 , A61K2039/70 , C07K14/005 , C12N2770/20022 , C12N2770/20034
摘要： The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo , into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering , in vivo , into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo , and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo . The SARS-CoV protein is also administered in an immunologically effective amount.
摘要翻译：本发明涉及通过在体内向脊椎动物的组织中施用至少一种包含一个或多个编码SARS-CoV蛋白或片段的核酸区域的多核苷酸来提高脊椎动物中的可检测的免疫应答，变体，或其衍生物。本发明还涉及通过在体内施用脊椎动物组织，至少一种SARS-CoV蛋白或其片段，变体或衍生物来提高脊椎动物中的可检测的免疫应答。 SARS-CoV蛋白可以是例如纯化形式。将多核苷酸体内掺入脊椎动物的细胞中，在体内产生免疫有效量的SARS-CoV多肽，片段，变体或衍生物的免疫原性表位。 SARS-CoV蛋白也以免疫有效量施用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式